Maximum quantity allowed is 999
请选择数量
CAS RN: 14892-97-8 | 產品號碼: C3577
產品號碼 | C3577 |
純度/分析方法 ![]() |
>98.0%(HPLC) |
分子式 / 分子量 | C__1__8H__1__2N__4OS = 332.38 |
外觀與形狀(20°C) | Solid |
儲存條件 ![]() |
Refrigerated (0-10°C) |
應避免的情況 | Heat Sensitive |
包裝和容器 ![]() |
10MG-Glass Bottle with Plastic Insert (閲覽圖片), 50MG-Glass Bottle with Plastic Insert (閲覽圖片) |
CAS RN | 14892-97-8 |
Reaxys-RN | 306520 |
PubChem Substance ID | 468591173 |
MDL編號 | MFCD02167478 |
產品規格
Appearance | White to Yellow to Green powder to crystal |
Purity(HPLC) | min. 98.0 area% |
Melting point | 207.0 to 211.0 °C |
Elemental analysis(Nitrogen) | 16.00 to 17.50 % |
NMR | confirm to structure |
性質
熔點 | 209 °C |
Maximum Wavelength | 380 nm |
GHS
相關法規
運輸資料
HS編碼* | 2933.99-000 |
Application
CRISPR Genome Editing
SCR7 Pyrazine enhances CRISPR-mediated homology-directed repair (HDR) efficiency.
References
- Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing of HSV-1 virus in human cells
Application
DNA Ligase Inhibitor: SCR7 Pyrazine
References
- CRISPR-Cas systems for editing, regulating and targeting genomes
- Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining
- Increasing the efficiency of homology-directed repair for CRISPR-Cas9-induced precise gene editing in mammalian cells
- An Inhibitor of Nonhomologous End-Joining Abrogates Double-Strand Break Repair and Impedes Cancer Progression
- SCR7 is neither a selective nor a potent inhibitor of human DNA ligase IV
- Synthesis and structure determination of SCR7, a DNA ligase inhibitor
- Autocyclized and oxidized forms of SCR7 induce cancer cell death by inhibiting nonhomologous DNA end joining in a Ligase IV dependent manner
- Water-soluble version of SCR7-pyrazine inhibits DNA repair and abrogates tumor cell proliferation
文檔
產品文件 (部分產品的分析圖譜無法提供,敬請諒解。)
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助,請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注:該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉,您搜索的分析圖譜無法提供。